Abstract: The protective effect on peritoneum of L-carnitine and its lower alkanoyl derivatives, both in the form of inner or pharmaceutically acceptable salts is disclosed. Concentrations of carnitine from about 0.02 to 0.5% w/v are suitable for preparing a solution for peritoneal dialysis having higher biocompatibility and protecting peritoneum from toxic effects of continuous use of solutions for peritoneal dialysis, in particular ones containing glucose as osmotic agent. A particularly preferred embodiment is a solution for peritoneal dialysis containing carnitine, glucose and xylitol.

Abstract: Formula (I) compounds are described in which the substituents have the meanings described in the text, and which are useful for the treatment of diseases responding to PPAR?activation, such as heart failure, the hyperlipaemias and atherosclerosis.

Abstract: Cell membrane maintenance of red blood cells and platelet concentrates is improved by the addition of 1 mM-10 mM L-carnitine and derivatives. This improvement allows extension of the period of viability of packed red blood cells and platelet concentrations beyond current periods. Additionally, the materials so treated exhibit extended circulation half life upon transhision to a patient. Improvements in membrane maintenance achieved by this method permit irradiation of sealed containers of blood products so as to substantially sterilize and destroy leukocytes in the same.

Abstract: The use of L-carnitine and its alkanoyl derivatives, optionally in the form of a pharmaceutically acceptable salt, as osmotic agents in the preparation of solutions for medical use, particularly for peritoneal dialysis, is described.

Abstract: The use of L-carnitine and its alkanoyl devivatives, optionally in the form of a pharmaceutically acceptable salt, as osmotic agents in the preparation of solutions for medical use, particularly for peritoneal dialysis, is described.

Abstract: A storage solution to maintain and perfuse organs awaiting transplantation comprising (a) an isotonic balanced solution comprising a physiologically acceptable amount of potassium, mono acidic phosphate, biacidic phosphate, chloride, sodium and bicarbonate ions; (b) 50-250 mM glucose; (c) 0.2-20 mM of an alkanoyl L-carnitine or a physiologically acceptable salt thereof; (d) 1-100 mM of L-carnitine or a physiologically acceptable salt thereof; (e) water is described. The storage solution can also include other components such as anti-oxidants and/or chelating agents.

Abstract: The use of fibrates, particularly clofibrate, is described for the preparation of a medicament useful in the treatment of congestive heart failure, and particularly the states of heart failure unrelated to dyslipidaemic conditions.

Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.

Abstract: Compounds of formula (I) 1

Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.

Abstract: The invention described herein relates to the use of L-carnitine or one of its alkanoyl derivatives with formula (I) where R is an alkanoyl group with from 2 to 8 carbon atoms, and X− is the acid fumarate anion, for the preparation of a medicine useful in the treatment and prevention of organ ischemia.

Abstract: A pharmaceutical composition is described, comprising a lipid-lowering drug such as lovastatin, simvastatin, pravastatin and fluvastatin and L-carnitine or an alkanoyl L-carnitine, which, while conserving the efficacy of the lipid-lowering drug, is substantially devoid of the toxic or side effects typical of such drugs.

Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.

Abstract: Solutions which contain L-carnitine and alkanoyl L-carnitine are useful for stabilizing blood for transfusions.